CSIMarket
 
Celgene Corp  (CELG)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 730
 Employees 6,012
 Revenues (TTM) (Millions $) 16,982
 Net Income (TTM) (Millions $) 1,834
 Cash Flow (TTM) (Millions $) 7,124
 Capital Exp. (TTM) (Millions $) 695

Celgene Corp
We are a multinational integrated biopharmaceutical company, incorporated in 1986 as a Delaware corporation. We are primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory-related diseases. Over the last several years, total revenues have steadily grown led by sales of THALOMID(R) (thalidomide), our lead product, which is currently marketed for the treatment of erythema nodosum leprosum, or ENL, but more widely used off-label for treating multiple myeloma and other cancers. The sales growth of THALOMID(R) has enabled us to make substantial investments in research and development, which has advanced our broad portfolio of drug candidates in our product pipeline, including a pipeline of IMiDs(R) compounds, which are a class of compounds proprietary to us and having certain immunomodulatory and other biologically important properties.


   Company Address: 86 Morris Avenue Summit, 7901 NJ
   Company Phone Number: 673-9000   Stock Exchange / Ticker: NASDAQ CELG
   


Customers Net Income grew by CELG's customers Net margin grew to

25.62 %

4.05 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
LLY        6.92% 
BMY        3.24% 
MRK        5.25% 
ABT   -0.94%    
PFE        2.41% 
JNJ        3.55% 
• View Complete Report
   



Enbridge Inc

Income Positive Again, Modest Revenue Increase

Enbridge Inc announced earnings per share of $0.72 and Sales of $7.67 billions in the first quarter of 2021, Company's earnings turn positive per share, versus $-0.54 eps, earned in the same quarter a year ago, although Enbridge Inc saw its Sales rise by 1.45% in the same period.

In comparison to previous quarter income improved by 7 % from $0.67 per share and Sales improved by 21.77 % from $7.67 billions.

Cyberoptics Corp

Impressive Income Growth, Sales are Up

Sales for the most recent fiscal period increased by 7.93% to $17.73 millions in comparison to $16.43 millions on a year-over-year basis, company posted earnings growth of 72.73 % to $0.19, as comparison at $0.11 in the prior year quarter.

In contrast to the fourth quarter Sales increased by 5.1 % from $16.87 millions and eps decreased by -3.02% from $0.20 per share.

O Reilly Automotive Inc

O Reilly Automotive Inc announced fiscal period ending Mar 31 2021 operating surplus of $691.105 millions

O Reilly Automotive Inc showed respectable growth in the fiscal period ending Mar 31 2021, where income surged by 77.83 % year on year to $7.06 per share and Sales increased by 24.81% to $3.09 billions.

Sequentially earnings grew by 30.74 % from $5.40 per share and Sales advanced by 9.27 % from $2.83 billions.

Tanger Factory Outlet Centers Inc

Tanger Factory Outlet Centers Inc announced first quarter of 2021 operating profit of $20.44 millions

first quarter of 2021 was profitable despite lower revenues, earnings turn positive to $0.04 per share compared to $-0.30 loss, while Sales declined by -9.8% to $100.69 millions from $111.63 millions, compared to first quarter of 2021 a year ago.

In the previous quarter company realized Sales of $111.16 millions and bottom line of $0.00 per share.

Nektar Therapeutics

Losses Widen, Sales Faded

Weak demand caused increase in losses for the financial time frame ending Mar 31 2021, company's deficit per share grew to $-0.68 from $-0.64 where Sales fell by -30.17% to $23.65 millions from $33.86 millions a year ago.

In contrast to the third quarter Sales fell by -21.26% from $30.03 millions and increased losses from $-0.61 per share.






 

Celgene's Segments
 
REVLIMID
 Segment    62.85 % of total Revenue
THALOMID
 Segment    1.95 % of total Revenue
ABRAXANE
 Segment    9.94 % of total Revenue
VIDAZA
 Segment    6.38 % of total Revenue
Other
 Segment    0.12 % of total Revenue
Total product sales
 Segment    100 % of total Revenue
ISTODAX
 Segment    0.75 % of total Revenue
POMALYST, IMNOVID
 Segment    11.09 % of total Revenue
azacitidine injection
 Segment    0.92 % of total Revenue
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Celgene does not provide revenue guidance.

Earnings Outlook
Nektar Therapeutics does not provide earnings estimates.

 
Geographic Revenue Dispersion
United States 59.47 %
All Other 11.8 %
Europe 28.73 %


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

AMC's Profile

Stock Price

AMC's Financials

Business Description

Fundamentals

Charts & Quotes

AMC's News

Suppliers

AMC's Competitors

Customers & Markets

Economic Indicators

AMC's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071